COVID-19 Vaccine Response

Overview

Vaccination remains the main promising measure to fight against the COVID-19 pandemic. The presumed efficacy of the vaccines is quite remarkable since it varies between 62 and 95%. There is increasing evidence that sex-specific effects may lead to different outcomes of vaccine safety and efficacy. However, sex-disaggregated data after COVID-19 vaccine are lacking. The first purpose of the study is to determine antibody titers against SARS-CoV-2 spike after COVID-19 vaccination. The secondary purpose is to identify predictor factors of immune response including age, gender and biological factors.

Full Title of Study: “Follow-up of COVID-19 Vaccine Response in Strasbourg University Hospitals”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: April 8, 2022

Clinical Trial Outcome Measures

Primary Measures

  • Study of the relationship between the serological response to the COVID-19 vaccine and the demographic characteristics of the patient
    • Time Frame: up to 1 month post-vaccination

Participating in This Clinical Trial

Inclusion Criteria

  • Any person, male or female, over 18 years of age who underwent vaccination and – anti-SARS-CoV-2 serological test after vaccination – having already given their consent for their biological resources to be: – stored in a biocollection of the Microbiology Technical Platform (PTM) having received an approval from the CPP Est-IV and declared to the Ministry of Education and Research under reference No. DC2009-1002; – subsequently reused, as well as the anonymized associated data, for research purposes Exclusion Criteria:

  • Inability to give clear information (person in an emergency, difficulty understanding the subject, etc.) – Person under safeguard of justice – Person under guardianship or curatorship-

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • University Hospital, Strasbourg, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Samira FAFI-KREMER, PharmD, PhD, Study Director, Service de Virologie – Hôpital Civil
  • Overall Contact(s)
    • Samira FAFI-KREMER, PharmD, PhD, 33.3.69.55.14.38, Samira.fafi-kremer@chru-strasbourg.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.